TrialJournal for immunotherapy of cancer2022

Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer.

Stephanie Lheureux et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.